Quarterly Result29 May 2026, 08:22 pm
Welcure Drugs: Audited Standalone Results for FY26
AI Summary
Welcure Drugs & Pharmaceuticals Ltd has announced its audited standalone financial results for the quarter and year ended March 31, 2026. The announcement was made following a Board of Directors meeting held on May 29, 2026. The auditors have issued an unmodified opinion on the financial results. However, the auditor has emphasized on uncertainties related to trade receivables, trade payables, and loans and advances, and the lack of MSME creditor bifurcation support.
Key Highlights
- Welcure Drugs announces audited standalone financial results for the quarter and year ended March 31, 2026.
- Auditors issued an unmodified opinion on the audited standalone financial results.
- Auditor highlights uncertainties regarding trade receivables, payables, loans, and advances.
- Supporting documentation for MSME creditor bifurcation of ₹19946.50 not provided.
Price Impact
More from WELCURE